What are Kyverna Therapeutics, Inc.'s total assets?

Kyverna Therapeutics, Inc. (KYTX) holds $257.0M in total assets, down 1.4% year over year.

How much debt does Kyverna Therapeutics, Inc. have?

Kyverna Therapeutics, Inc. carries $9.2M in total debt against $195.6M of shareholders' equity, a debt-to-equity ratio of 0.05.

How much cash does Kyverna Therapeutics, Inc. have?

Kyverna Therapeutics, Inc. holds $32.2M in cash and equivalents.

Can Kyverna Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 8.15 — current assets exceed current liabilities.

Where does Kyverna Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kyverna Therapeutics, Inc. KYTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$32.19M-74.1%	$124.09M+263%	$34.16M-36.1%	$53.44M-6.0%	$56.87M-41.1%
Short-term investments	$204.25M+31.6%	$155.16M+13.3%	$136.97M-13.4%	$158.24M-14.8%	$185.78M-1.9%
Restricted cash	$551K0.0%	$551K0.0%	$551K0.0%	$551K-1.1%	$557K+0.9%
Prepaid expenses and other current assets	$5.28M+42.7%	$3.7M-2.3%	$3.79M+42.9%	$2.65M-47.0%	$5M+8.2%
Total current assets	$241.73M-14.6%	$282.95M+61.8%	$174.93M-18.4%	$214.33M-13.5%	$247.65M-14.8%
Property and equipment, net	$1.34M-13.1%	$1.55M-13.8%	$1.79M-17.1%	$2.16M-11.2%	$2.44M-27.2%
Operating lease right-of-use assets	$8.19M+130%	$3.57M-17.4%	$4.32M-14.5%	$5.05M-12.4%	$5.76M-10.9%
Other non-current assets	$5.01M+2.3%	$4.9M-8.5%	$5.36M+32.2%	$4.05M+11.2%	$3.64M+28.5%
Total assets	$257.02M-12.5%	$293.83M+57.0%	$187.16M-17.4%	$226.51M-13.1%	$260.66M-14.4%
Accounts payable	$11.6M+119%	$5.31M+75.9%	$3.02M-69.6%	$9.92M+17.1%	$8.47M+83.2%
Accrued compensation	$3.11M-68.8%	$9.99M+43.5%	$6.96M+40.0%	$4.97M+61.4%	$3.08M-36.9%
Current portion of long-term debt	$221K-28.0%	$307K+61.6%	$190K-34.9%	$292K-42.4%	$507K-34.9%
Operating lease liabilities, current	$1.76M-51.8%	$3.66M+4.8%	$3.5M+6.4%	$3.28M+6.7%	$3.08M-2.6%
Finance Lease Liability, Current	$221K-28.0%	$307K+61.6%	$190K-34.9%	$292K-42.4%	$507K-34.9%
Total current liabilities	$29.67M-18.7%	$36.49M+7.7%	$33.87M-14.9%	$39.79M+19.5%	$33.29M-1.4%
Operating lease liabilities, non-current	$6.96M+2,074%	$320K-76.0%	$1.33M-42.5%	$2.32M-29.4%	$3.28M-21.2%
Finance Lease Liabilities (Total)	$221K-28.0%	$307K—	——	——	——
Operating Lease Liabilities (Total)	$8.72M+119%	$3.98M—	——	——	——
Finance lease liabilities	$0—	$0-100%	$8K-69.2%	$26K-64.4%	$73K-48.6%
Total liabilities	$61.44M-0.2%	$61.55M+74.8%	$35.21M-16.4%	$42.13M+15.0%	$36.65M-3.7%
Preferred stock	$0—	$0—	——	——	——
Common stock	$1K0.0%	$1K—	——	——	——
Additional paid-in capital	$660.23M+0.5%	$657.01M+21.9%	$538.94M+0.8%	$534.63M+0.5%	$532.17M+0.4%
Retained earnings	-$464.56M-9.4%	-$424.83M-9.8%	-$387.02M-10.5%	-$350.24M-13.7%	-$308.16M-16.9%
Accumulated other comprehensive income (loss)	-$96K-199%	$97K+234%	$29K+245%	-$20K-1,900%	-$1K-101%
Total stockholders' equity	$195.58M-15.8%	$232.28M+52.9%	$151.95M-17.6%	$184.38M-17.7%	$224.01M-16.0%
Total liabilities and stockholders' equity	$257.02M-12.5%	$293.83M+57.0%	$187.16M-17.4%	$226.51M-13.1%	$260.66M-14.4%
Short- term Investments	$204.25M+31.6%	$155.16M+13.3%	$136.97M-13.4%	$158.24M-14.8%	$185.78M-1.9%
Deferred Tax Assets and Other Non-Current Assets	$5.01M+2.3%	$4.9M-8.5%	$5.36M+32.2%	$4.05M+11.2%	$3.64M+28.5%
Net Investment in Lease	$8.19M+130%	$3.57M-17.4%	$4.32M-14.5%	$5.05M-12.4%	$5.76M-10.9%
Operating lease right-of-use assets	$8.19M+130%	$3.57M-17.4%	$4.32M-14.5%	$5.05M-12.4%	$5.76M-10.9%
Other non-current assets	$5.01M+2.3%	$4.9M-8.5%	$5.36M+32.2%	$4.05M+11.2%	$3.64M+28.5%
Operating Lease Right-of-Use Assets in Other Assets	$8.19M+130%	$3.57M-17.4%	$4.32M-14.5%	$5.05M-12.4%	$5.76M-10.9%
Software and Technology Licenses, Net	$5.01M+2.3%	$4.9M-8.5%	$5.36M+32.2%	$4.05M+11.2%	$3.64M+28.5%
Accrued License Expense Related Party	$3.75M0.0%	$3.75M-40.0%	$6.25M0.0%	$6.25M0.0%	$6.25M0.0%
Other Accrued Expenses And Current Liabilities	$9.22M-31.5%	$13.47M-3.5%	$13.96M-7.4%	$15.08M+26.6%	$11.91M-15.3%
Line of Credit Outstanding	$24.81M+0.3%	$24.74M—	——	——	——
Total debt	$9.16M+99.4%	$4.6M-8.5%	$5.02M-15.1%	$5.92M-14.7%	$6.94M-23.1%
Additional paid-in capital	$660.23M+0.5%	$657.01M+21.9%	$538.94M+0.8%	$534.63M+0.5%	$532.17M+0.4%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1K0.0%	$1K—	——	——	——
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——	——	——
Current maturities of long-term debt	$221K-28.0%	$307K+61.6%	$190K-34.9%	$292K-42.4%	$507K-34.9%
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$198K-35.1%	$305K+43.9%	$212K-42.1%	$366K-39.3%	$603K-28.3%
Secured lines of credit	$24.81M+0.3%	$24.74M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Kyverna Therapeutics, Inc.'s total assets?: Kyverna Therapeutics, Inc. (KYTX) holds $257.0M in total assets, down 1.4% year over year.
How much debt does Kyverna Therapeutics, Inc. have?: Kyverna Therapeutics, Inc. carries $9.2M in total debt against $195.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
How much cash does Kyverna Therapeutics, Inc. have?: Kyverna Therapeutics, Inc. holds $32.2M in cash and equivalents.
Can Kyverna Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 8.15 — current assets exceed current liabilities.
Where does Kyverna Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.